VERTEX PHARMACEUTICALS

World Rank (Jul-30-2023)
161
Market Cap (Jul-30-2023)
91.186 Billion USD
World Rank (Dec-25-2022)
182
Market Cap (Dec-25-2022)
74.361 Billion USD
World Rank (Jan-07-2022)
323
Market Cap (Jan-07-2022)
56.406 Billion USD
World Rank (Jan-01-2021)
249
Market Cap (Jan-01-2021)
61.457 Billion USD
Annual Revenue in USD
8,930 Million USD
Annual Net Income in USD
3,322 Million USD
Total Assets in USD
18,150 Million USD
Total Liabilities in USD
4,238 Million USD
Annual Results for Year ending in
Dec-2022 month
Headquarters State / City
Massachusetts
Headquarters Country
USA
Headquarters Sub Region
Northern America
Headquarters Continent
Americas
Company Business
Healthcare
Pharmaceutical
Biotechnology
Biopharmaceutical
HealthCare Products
Stock Category
S&P 500
Nasdaq 100
Stock Exchange
Nasdaq
Bovespa Brazil
Company Rank in Country in 2022
Company Rank in USA in 2022 is 158
Rank in Country (Jan-2021)
Company Rank in USA in 2021 is 130
Rank in Country (Jan-2020)
Rank in USA in 2020 is 119
Number of Employees
4,500
Employee Count as on Date
As on 2022
CEO:
Reshma Kewalramani
Founders
Joshua Boger
Yahoo @ Nasdaq
Wikipedia
Company Website:
Vertex Pharmaceuticals
Business Sector:
Top Technology Companies in USA
Top Healthcare Companies in USA
Top Technology Companies in S&P 500
Top Healthcare Companies in S&P 500
Top Pharmaceutical Companies in USA
Top Pharmaceutical Companies in S&P 500
Top Bio Pharmaceutical Companies in USA
About Company Business:

VERTEX PHARMACEUTICALS is USA Based Bio-Technology, Bio-Pharmaceutical and Healthcare Company.It have research and development sites, manufacturing facilities and offices around the world. The company locations are North America, Europe, Australia, South America.

As on 2022, VERTEX PHARMACEUTICALS has 4,500 employees.

VERTEX PHARMACEUTICALS annual revenue generated for period ending Dec-2022 was 8,930 million USD.

VERTEX PHARMACEUTICALS annual net income generated for period ending Dec-2022 was 3,322 million USD.

VERTEX PHARMACEUTICALS annual revenue generated for period ending Dec-2021 was 7,574 million USD.

Split of Annual Revenue by business segment  for period ending Dec-2021:

  • TRIKAFTA/KAFTRIO: 5,697 million USD.
  • SYMDEKO/SYMKEVI: 420 million USD.
  • ORKAMBI: 771 million USD.
  • KALYDECO: 684 million USD.
  • Other Revenue: 1 million USD.

VERTEX PHARMACEUTICALS annual net income generated for period ending Dec-2021 was 2,342 million USD.

Total Assets as on Dec-2021 was 13,432 Million USD.

Total Liabilities as on Dec-2021 was 3,332 Million USD.

Total Equity as on Dec-2021 was 10,100 Million USD.

IPO Year
1991
Founded Year
1989
Annual Results Summary:

VERTEX PHARMACEUTICALS - Annual Results - Revenue and Net Income - in Million USD:

Year - Ending Revenue Operating Income Net Income
Dec-2022 8,930 4,365 3,322
Dec-2021 7,574 2,782 2,342
Dec-2020 6,205 2,869 2,711
Dec-2019 4,163 1,202 1,177
Dec-2018 3,047 664 2,097
Dec-2017 2,488 392 263
Dec-2016 1,702   -112
Balance Sheet Summary

VERTEX PHARMACEUTICALS - Balance Sheet Summary - in Million USD:

Year Ending:

 Total Assets Total Liabilities Total Equity
Dec-2022 18,150 4,238 13,912
Dec-2021 13,432 3,332 10,100
Dec-2020 11,752 3,065 8,687
Dec-2019 8,318 2,233 6,085
Dec-2018 6,246 1,811 4,435
Dec-2017 3,546 1,517 2,029
Quarterly Results Summary:

VERTEX PHARMACEUTICALS - Quarterly Results - Revenue and Net Income - in Million USD:

Quarterly Ending:

 Total Revenue Operating Income Net Income
Jun-2023 2,493 1,136 915
Mar-2023 2,374 1,124 699
Dec-2022 2,302 1,057 818
Sep-2022 2,334 1,153 930
Jun-2022 2,196 1,119 810
Mar-2022 2,097 1,033 762
Dec-2021 2,072 877 770
Sep-2021 1,984 1,055 852
Jun-2021 1,793 -38 67
Mar-2021 1,724 888 653
Dec-2020 1,628 746 604
Institutional Investors

Top 30 Institutional Holder Names in VERTEX PHARMACEUTICALS as on MAR-31-2023

RANK Institutional Investors DATE SHARES HELD CHANGE (SHARES) CHANGE (%) VALUE (IN 1,000S)
1 BLACKROCK INC. 3/31/2023 23,906,603 -334,834 -1.38% $8,250,408
2 VANGUARD GROUP INC 3/31/2023 21,846,152 299,249 1.39% $7,539,326
3 FMR LLC 3/31/2023 16,275,855 -1,590,436 -8.90% $5,616,960
4 CAPITAL WORLD INVESTORS 3/31/2023 16,144,423 3,375,417 26.43% $5,571,602
5 STATE STREET CORP 3/31/2023 12,207,452 -162,978 -1.32% $4,212,914
6 ALLIANCEBERNSTEIN L.P. 3/31/2023 8,373,273 -696,307 -7.68% $2,889,700
7 WELLINGTON MANAGEMENT GROUP LLP 3/31/2023 7,517,548 689,965 10.11% $2,594,381
8 PRICE T ROWE ASSOCIATES INC /MD/ 3/31/2023 6,590,190 1,892,523 40.29% $2,274,340
9 JPMORGAN CHASE & CO 3/31/2023 6,360,758 870,350 15.85% $2,195,161
10 GEODE CAPITAL MANAGEMENT, LLC 3/31/2023 5,409,257 26,538 0.49% $1,866,789
11 MASSACHUSETTS FINANCIAL SERVICES CO /MA/ 6/30/2023 3,941,121 -103,910 -2.57% $1,360,120
12 JENNISON ASSOCIATES LLC 6/30/2023 3,805,641 -774,160 -16.90% $1,313,365
13 AMERIPRISE FINANCIAL INC 3/31/2023 3,389,860 -188,787 -5.28% $1,169,875
14 LOOMIS SAYLES & CO L P 3/31/2023 3,371,646 -387,524 -10.31% $1,163,589
15 CLEARBRIDGE INVESTMENTS, LLC 3/31/2023 3,337,741 -148,379 -4.26% $1,151,888
16 UBS ASSET MANAGEMENT AMERICAS INC 3/31/2023 2,811,731 -117,685 -4.02% $970,356
17 NORTHERN TRUST CORP 3/31/2023 2,776,695 -74,864 -2.63% $958,265
18 BANK OF AMERICA CORP /DE/ 3/31/2023 2,585,144 88,084 3.53% $892,159
19 NORGES BANK 12/31/2022 2,451,521 -173,227 -6.60% $846,044
20 MORGAN STANLEY 3/31/2023 2,353,061 -225,383 -8.74% $812,065
21 LEGAL & GENERAL GROUP PLC 3/31/2023 2,086,331 52,967 2.61% $720,014
22 AMUNDI 3/31/2023 2,038,918 -91,279 -4.29% $703,651
23 BANK OF NEW YORK MELLON CORP 6/30/2023 1,997,457 -40,447 -1.99% $689,342
24 INVESCO LTD. 3/31/2023 1,861,368 236,469 14.55% $642,377
25 HARDING LOEVNER LP 3/31/2023 1,826,624 -13,897 -0.76% $630,386
26 DEUTSCHE BANK AG\ 3/31/2023 1,756,160 -96,922 -5.23% $606,068
27 GOLDMAN SACHS GROUP INC 3/31/2023 1,711,731 39,358 2.35% $590,735
28 CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 6/30/2023 1,467,618 -12,127 -0.82% $506,490
29 CHARLES SCHWAB INVESTMENT MANAGEMENT INC 3/31/2023 1,443,137 27,109 1.91% $498,041
30 RENAISSANCE TECHNOLOGIES LLC 3/31/2023 1,397,735 -849,017 -37.79% $482,372

Share it on Social Media